Digital therapeutics company aims for European expansion with new funding led by Mutuelles Impact
Berlin-based healthtech startup HelloBetter announced in March 2025 that it has raised over €6 million in equity funding to expand its digital therapy offerings across Europe. The round was led by Mutuelles Impact (managed by XAnge) – a €95 million Franco-German fund focused on social and environmental impact in healthcare – alongside existing investors MMV, HealthCap, Expon, and DvH Ventures. HelloBetter intends to utilize the funding to expand into the French market, introduce new AI-driven mental health solutions, and obtain regulatory approvals for its digital therapy programs locally.
HelloBetter develops clinically validated online therapy courses (known as prescription digital therapeutics, or PDTx) that are covered by health insurance in Germany. Its platform offers ten scientifically tested programs targeting stress, burnout, anxiety, panic, chronic pain and other conditions. With a team of over 150 employees and more than 120,000 patients treated, HelloBetter has been fully integrated into the German healthcare system, where doctors prescribe it and patients access the program through the app, typically at no extra cost. Six of its therapy courses have already received certification from Germany’s Federal Institute for Drugs and Medical Devices, qualifying them for reimbursement.
Investor commentary highlights the strategic fit. Nadja Bresous Mehigan, partner at XAnge Impact, said the fund is “thrilled to support the German leader in Prescription-DTx” as it expands into France. She noted that HelloBetter has “proven significant volumes of prescription activations” in Germany and is well-positioned to scale across Europe. Co-founder and CEO Hannes Klöpper stated that the funding will support HelloBetter in establishing itself as a well-known mental health brand in Germany, advancing new product development, and utilizing XAnge’s network of 65 partner health insurers to expand into the French market.
The funding round underscores growing investor interest in digital mental health and teletherapy. According to industry reports, women’s and mental health startups attracted record VC funding in 2024 across Europe and the US. HelloBetter’s success – particularly its insurance-backed model – illustrates this trend. By combining cognitive-behavioural therapy delivered via app and supportive coaching, the company addresses the well-documented shortage of mental health providers with a scalable tech solution.
Market analysts say HelloBetter is well-positioned: its backers highlight both the social impact and the business case. For example, HealthCap (an early investor) comments on its website that digital treatment programs can reduce healthcare costs and improve outcomes through measurable data. The new capital will primarily fund product and market development. According to HelloBetter’s announcement, the team will enhance its platform with AI-driven personalisation and build partnerships with payers and clinicians in new regions.
In the broader startup ecosystem, HelloBetter’s raise is a bellwether for digital health. The round’s lead investor – an impact fund – signals that public-sector healthcare stakeholders are eager for technology solutions in preventive and therapeutic care. It also reflects a shift: whereas traditional pharma and therapy were once slow-moving, “prescription digital therapeutics” are now attracting bold bets from venture and impact investors alike.
For HelloBetter’s founders, the funding round validates years of clinical research and commercial traction. They emphasise that their courses are not only evidence-based but also fill a vital gap in care. As CEO Klöpper notes, this financing “will enable us to do three things: become a household name for mental health in Germany, launch new, innovative products, and…bring our proven digital mental health solutions to the French market”. With this boost, HelloBetter is poised to accelerate the adoption of app-based therapy and tap into one of Europe’s fastest-growing healthcare segments.
